Literature DB >> 12829691

Atypical recognition consensus of CIN85/SETA/Ruk SH3 domains revealed by target-assisted iterative screening.

Alexei V Kurakin1, Susan Wu, Dale E Bredesen.   

Abstract

Target-assisted iterative screening applied to random peptide libraries unveiled a novel and atypical recognition consensus shared by CIN85/SETA/Ruk SH3 domains, PX(P/A)XXR. Confirmed by mutagenesis and in vitro binding experiments, the novel consensus allowed for the accurate mapping of CIN85 SH3 binding sites within known CIN85 interactors, c-Cbl, BLNK, Cbl-b, AIP1/Alix, SB1, and CD2 proteins, as well as the prediction of CIN85 novel-interacting partners in protein databases. Synaptojanin 1, PAK2, ZO-2, and TAFII70, which contain CIN85 SH3 recognition consensus sites, were selectively precipitated from mouse brain lysates by CIN85 SH3 domains in glutathione S-transferase pull-down experiments. A direct interaction of synaptojanin 1 and PAK2 with CIN85 SH3 domains was confirmed by Far Western blotting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829691     DOI: 10.1074/jbc.M305264200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking.

Authors:  Hye-Young Yoon; Stephen C Kales; Ruibai Luo; Stanley Lipkowitz; Paul A Randazzo
Journal:  Biol Cell       Date:  2011-04       Impact factor: 4.458

2.  CIN85 associates with multiple effectors controlling intracellular trafficking of epidermal growth factor receptors.

Authors:  Katarzyna Kowanetz; Koraljka Husnjak; Daniela Höller; Marcin Kowanetz; Philippe Soubeyran; Dianne Hirsch; Mirko H H Schmidt; Kresimir Pavelic; Pietro De Camilli; Paul A Randazzo; Ivan Dikic
Journal:  Mol Biol Cell       Date:  2004-04-16       Impact factor: 4.138

3.  An unconventional IAP-binding motif revealed by target-assisted iterative screening (TAIS) of the BIR3-cIAP1 domain.

Authors:  Alexei Kurakin; Dale E Bredesen
Journal:  J Mol Recognit       Date:  2007 Jan-Feb       Impact factor: 2.137

4.  CIN85 interacting proteins in B cells-specific role for SHIP-1.

Authors:  Tom Büchse; Nikolaus Horras; Eva Lenfert; Gerald Krystal; Sandra Körbel; Michael Schümann; Eberhard Krause; Stefan Mikkat; Markus Tiedge
Journal:  Mol Cell Proteomics       Date:  2011-07-01       Impact factor: 5.911

5.  The penta-EF-hand protein ALG-2 interacts directly with the ESCRT-I component TSG101, and Ca2+-dependently co-localizes to aberrant endosomes with dominant-negative AAA ATPase SKD1/Vps4B.

Authors:  Keiichi Katoh; Hidenori Suzuki; Yoshinori Terasawa; Takako Mizuno; Jiro Yasuda; Hideki Shibata; Masatoshi Maki
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

6.  Clues to CD2-associated protein involvement in cytokinesis.

Authors:  Pascale Monzo; Nils C Gauthier; Frédérique Keslair; Agnès Loubat; Christine M Field; Yannick Le Marchand-Brustel; Mireille Cormont
Journal:  Mol Biol Cell       Date:  2005-03-30       Impact factor: 4.138

7.  CIN85 modulates the down-regulation of Fc gammaRIIa expression and function by c-Cbl in a PKC-dependent manner in human neutrophils.

Authors:  Louis Marois; Myriam Vaillancourt; Guillaume Paré; Valérie Gagné; Maria J G Fernandes; Emmanuelle Rollet-Labelle; Paul H Naccache
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

8.  Herpes simplex virus 1 infected cell protein 0 forms a complex with CIN85 and Cbl and mediates the degradation of EGF receptor from cell surfaces.

Authors:  Yu Liang; Alexei Kurakin; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-11       Impact factor: 11.205

9.  Novel mediators of amyloid precursor protein signaling.

Authors:  Andrzej Swistowski; Qiang Zhang; Mark E Orcholski; Danielle Crippen; Cathy Vitelli; Alexei Kurakin; Dale E Bredesen
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

10.  State and role of SRC family kinases in replication of herpes simplex virus 1.

Authors:  Yu Liang; Bernard Roizman
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.